Skip to content

The Influence of Different At-home Exercise Strategies on 24h Glycemic Control

The Influence of Different At-home Exercise Strategies on 24h Glycemic Control in Women at Risk for With Metabolic Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05490706
Enrollment
107
Registered
2022-08-08
Start date
2022-07-07
Completion date
2023-04-30
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Disturbance

Keywords

women, glycemic control, exercise

Brief summary

This study will determine how different at-home exercise strategies influence 24hr glycemic control in women with metabolic dysfunction.

Detailed description

Elevations in blood glucose concentration increase risk for cardiometabolic diseases including type 2 diabetes and cardiovascular diseases. Exercise can improve glycemic control, but there is limited research comparing the effectiveness of different exercise strategies in women. The aim of this study is to examine, under free-living conditions, how performing either walking and bodyweight interval exercise after dinner influences glycemic control in women with or at risk for type 2 diabetes. Glycemic control will be measured with continuous glucose monitors.

Interventions

BEHAVIORALBodyweight interval exercise

Performing 15 minutes of bodyweight interval exercise after dinner at home by following a video

BEHAVIORALWalking

Performing a 30 minute minute walk after dinner at home

Sponsors

University of Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Females * no cancer history * ≥50 years old * Have metabolic dysfunction (defined as self-reported diagnosis of pre-diabetes, type 2 diabetes, or at least moderate Canadian diabetes risk (CANRISK) score) * Owns a smartphone with Bluetooth capability with Apple or Android operating system * deemed safe to exercise as per the CSEP Get Active Questionnaire * Enrolled in NCT05454943

Exclusion criteria

* Type 1 diabetes * Taking exogenous insulin, sulfonylureas, or GLP-1 receptor agonists * Self-reported history of an eating disorder * BMI \<18.5 kg/m * Working night or rotating shifts * Eating window \<12 hours or consistently eating less than 3 meals/day in the past 3 months * Major dietary changes within the past 3 months (i.e. calorie counting, ketogenic diet)

Design outcomes

Primary

MeasureTime frameDescription
24hr Glucose area under the curve24 hoursGlucose area under the curve over 24hr

Secondary

MeasureTime frameDescription
Postprandial dinner glucose response2 hoursMeasured as the 2hr postprandial glucose incremental area under the curve (iAUC), average glucose and peak glucose
Postprandial breakfast glucose response2 hoursMeasured as the 2hr postprandial iAUC, average glucose and peak glucose
Postprandial lunch glucose response2 hoursMeasured as the 2hr postprandial glucose iAUC, average glucose and peak glucose
Nocturnal glucose~6-8 hoursMeasured as the overnight glucose average and AUC
Time in hyperglycemia24 hoursTime (minutes and percent per day) above 10mmol/L over 24hr
Time in hypoglycemia24 hoursTime (minutes and percent per day) under 3.9mmol/L over 24 hr
24hr Average glucose concentration24 hoursAverage glucose concentration over 24 hr
Continuous overall net glycemic action (CONGA)24 hoursCalculated measure of glycemic variability
Change in glucose during exercise15-30 minutesPost vs. pre glucose concentration around exercise
Mean amplitude glycemic excursion (MAGE)24 hoursCalculated measure of glycemic variability
Standard deviation (SD)24 hoursCalculated measure of glycemic variability
% coefficient of variation (CV)24 hoursCalculated measure of glycemic variability
Time in range24 hoursTime (minutes and percent per day) above 3.9 but under 10mmol/L

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026